|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2018
gptkb:FDA
|
|
gptkbp:availability
|
available in pharmacies
|
|
gptkbp:brand
|
gptkb:Emgality
|
|
gptkbp:chemical_formula
|
C_40 H_57 N_7 O_12 S
|
|
gptkbp:class
|
CGRP inhibitors
|
|
gptkbp:clinical_trial
|
gptkb:EVOLVE-1
gptkb:EVOLVE-2
Phase III
REGAIN
|
|
gptkbp:clinical_use
|
preventive treatment for migraines
|
|
gptkbp:contraindication
|
hypersensitivity to galcanezumab
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:formulation
|
pre-filled syringe
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
galcanezumab-gnlm
|
|
gptkbp:indication
|
chronic migraine
episodic migraine
|
|
gptkbp:ingredients
|
gptkb:galcanezumab
|
|
gptkbp:invention
|
patented
|
|
gptkbp:market_launch
|
gptkb:2018
|
|
gptkbp:marketed_as
|
gptkb:Emgality
|
|
gptkbp:mechanism_of_action
|
CGRP receptor antagonist
|
|
gptkbp:patient_population
|
adults
|
|
gptkbp:pharmacokinetics
|
long half-life
inhibition of CGRP signaling
|
|
gptkbp:price
|
high cost
|
|
gptkbp:provides_guidance_on
|
gptkb:American_Academy_of_Neurology
gptkb:American_Headache_Society
|
|
gptkbp:research
|
CGRP and migraine
|
|
gptkbp:research_areas
|
neurology
pain management
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:service_frequency
|
once monthly
|
|
gptkbp:side_effect
|
gptkb:depression
anxiety
fatigue
nausea
insomnia
constipation
dry mouth
injection site reactions
hypersensitivity reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
CGRP (Calcitonin Gene-Related Peptide)
|
|
gptkbp:type_of_care
|
high adherence rates
|
|
gptkbp:type_of_insurance
|
covered by most insurance plans
|
|
gptkbp:used_for
|
migraine prevention
|
|
gptkbp:weight
|
877.01 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Emgality
|
|
gptkbp:bfsLayer
|
5
|